Phaseline

Companies › Beijing VDJBio

Beijing VDJBio: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 3; Immunology, Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VDJ001
IL-6 receptor antagonist monoclonal antibody
IL6RPhase 3Anti IL-6RJun 2027
Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
anti-IL-6 receptor monoclonal antibody
IL6RPhase 2Idiopathic Multicentric Castleman's Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05345522Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody InjectionPhase 2Idiopathic Multicentric Castleman's DiseaseImmunologyNov 2022
NCT07872423VDJ001Phase 3Anti IL-6ROncologyJun 2027

Targets

IL6R (2)

Companies with the same targets

Roche Biocad Johnson & Johnson (Janssen) Innovent Biologics (Suzhou) Sanofi R-Pharm Kodiak Sciences

Companies built like this

Tanabe Pharma Taizhou Mabtech Pharmaceutical RAPT Therapeutics, Inc., a member of the GSK plc group of companies CrystalGenomics Partner Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.